Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Last searches

Results for *

Displaying results 1 to 14 of 14.

  1. Mord ist eine Wissenschaft
    Was schon Agatha Christie über Rechtsmedizin wusste | Die Forensikerin über Blutspuren und Fingerabdruck, Giftmord und Obduktion
    Author: Valentine, Carla
    Published: 2022
    Publisher:  Droemer eBook, München

    Export to reference management software   RIS file
      BibTeX file
  2. Arzneistoffe in tiermedizinischen Standardwerken der römischen Antike.
    Lexikon und Konkordanz.
    Author: Sackmann, Werner
    Published: 2022
    Publisher:  Solivagus-Verlag, Kiel

    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Contributor: Eitel, Astrid (Publisher)
    Language: German; Latin
    Media type: Book
    Format: Print
    ISBN: 9783943025651; 3943025659
    Other identifier:
    9783943025651
    DDC Categories: 400
    Edition: 1. Auflage
    Other subjects: Veterinärmedizin; Therapie; Naturheilkunde; Philologie; Heilmittel; Tierarzneimittel; Mineralogie; Spätantike; Wissenschaftsgeschichte; Allopathie; Homöopathie; Lexikon; Pharmakologie; Schulmedizin; Pelagonius; Volksmedizin; Latein; Antike; Vegetius; Konkordanz
    Scope: 830 Seiten, 0 Illustrationen, 22.5 cm x 16 cm
  3. Studien zu Hippokrates, De internis affectionibus
    Author: Heinrich, Annette
    Published: 2022
    Publisher:  Humboldt-Universität zu Berlin, Berlin

    Export to reference management software   RIS file
      BibTeX file
  4. Mord ist eine Wissenschaft
    was schon Agatha Christie über Rechtsmedizin wusste
    Author: Valentine, Carla
    Published: Oktober 2022
    Publisher:  Droemer, München

    Export to reference management software   RIS file
      BibTeX file
    Content information
    Source: Union catalogues
    Contributor: Bernhardt, Christiane (Übersetzer)
    Language: German
    Media type: Book
    Format: Print
    ISBN: 9783426303009; 3426303000
    Other identifier:
    9783426303009
    Edition: Deutsche Erstausgabe
    Subjects: Kriminalfall; Spurensicherung; Forensik; Autopsie; Gerichtliche Toxikologie; Kriminalroman
    Other subjects: Christie, Agatha (1890-1976); (Produktform)Paperback / softback; (Produktform (spezifisch))Paperback (DE); True Crime; Echte Verbrechen; Agatha Christie; Klassiker; Forensik; Ballistik; Fingerabdrücke; Bestatterin; erzählendes Sachbuch; historischer Kriminalfall; Leiche; Mord; Rechtsmedizin; Rechtsmedizinerin; Abenteuerthriller; englische Polizei; Miss Marple; Hercule Poirot; Echte forensische Geschichten; Toxikologie; Fachbuch Kriminologie; Pharmakologie; Barts Pathology Museum London; Kuratorin; Michael Tsokos Bücher; Carla Valentine; Mord ist Wissenschaft; Forensik Bücher; Forensik Kriminalistik; Kriminaltechnik; Gerichtsmedizin Bücher; Literatur Klassiker; Bücher über Bücher; Bücher über Literatur; Agatha Christie Kriminalfälle; Agatha Christie Krimis; Agatha Christie Forensik; Agatha Christie Crime Scene; Agatha Christie Kriminaltechnik; Krimi Überführung Mörder; englische Krimis; britische Krimis; Gerichtsmedizin Krimi; Forensik Krimi; spannende Kriminalfälle; Ermittlungsmethoden; True Crime Bücher; (VLB-WN)2973: Taschenbuch / Sachbücher/Politik, Gesellschaft, Wirtschaft/Gesellschaft; (BISAC Subject Heading)POL028000
    Scope: 431 Seiten, Illustrationen, 21 cm, 395 g
  5. Inside the innovation lab
    how paradoxical tensions persist in ambidextrous organizations over time
    Author: Winther, Casper Hein
    Published: 2022
    Publisher:  Copenhagen Business School, Frederiksberg, Danmark

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    Keine Rechte
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Dissertation
    Format: Online
    ISBN: 9788775680924
    Edition: 1. udgave
    Series: PhD series / Copenhagen Business School ; 2022, 19
    Subjects: Innovationsmanagement; Organisationale Ambidextrie; Pharmakologie; Pharmaindustrie; Dänemark
    Scope: 1 Online-Ressource (circa 268 Seiten), Illustrationen
    Notes:

    Dissertation, Copenhagen Business School, 2022
  6. Calculating the Costs and Benefits of Advance Preparations for Future Pandemics
    Author: Glennerster, Rachel; Snyder, Christopher M.; Tan, Brandon Joel
    Published: October 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of lives and trillions of dollars. Combining estimates of the frequency and intensity of pandemics with estimates of mortality, economic-output, and human-capital losses from pandemics of varying severities, we calculate expected global losses from pandemics of over $800 billion annually. According to our model, spending $60 billion up front to expand production capacity for vaccines and supply-chain inputs and $5 billion every year thereafter would be sufficient to ensure production capacity to vaccinate 70% of the global population against a new virus within six months, generating an expected net present value (NPV) of over $400 billion. A proportionate advance-investment program undertaken by the United States alone would generate an expected NPV of $47 billion ($141 per capita)

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: NBER working paper series ; no. w30565
    Subjects: Coronavirus; Epidemie; Wirtschaftskrise; Wirkungsanalyse; Gesundheitspolitik; Investition; Pharmakologie; Pharmaindustrie; Technologiepolitik; Forschungsfinanzierung; Kosten-Nutzen-Analyse; USA; Publicly Provided Goods: Mixed Markets; Health and Economic Development; Government Policy; Regulation; Public Health; Chemicals; Rubber; Drugs; Biotechnology; Plastics
    Scope: 1 Online-Ressource, illustrations (black and white)
    Notes:

    Hardcopy version available to institutional subscribers
  7. Representation and Extrapolation
    Evidence from Clinical Trials
    Author: Alsan, Marcella; Durvasula, Maya; Gupta, Harsh; Schwartzstein, Joshua; Williams, Heidi
    Published: October 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    This article examines the consequences and causes of low enrollment of Black patients in clinical trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is more relevant for decision-making by physicians and... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    This article examines the consequences and causes of low enrollment of Black patients in clinical trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is more relevant for decision-making by physicians and patients when it is more representative of the group that is being treated. This generates the key result that the perceived benefit of a medicine for a group depends not only on the average benefit from a trial, but also on the share of patients from that group who were enrolled in the trial. In survey experiments, we find that physicians who care for Black patients are more willing to prescribe drugs tested in representative samples, an effect substantial enough to close observed gaps in the prescribing rates of new medicines. Black patients update more on drug efficacy when the sample that the drug is tested on is more representative, reducing Black-White patient gaps in beliefs about whether the drug will work as described. Despite these benefits of representative data, our framework predicts that those who have benefited more from past medical breakthroughs are less costly to enroll in the present, leading to persistence in who is represented in the evidence base

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: NBER working paper series ; no. w30575
    Subjects: Arzneimittel; Pharmakologie; Schwarze Menschen; USA; Role and Effects of Psychological, Emotional, Social, and Cognitive Factors on Decision Making; National Government Expenditures and Related Policies; Health and Inequality
    Scope: 1 Online-Ressource, illustrations (black and white)
    Notes:

    Hardcopy version available to institutional subscribers
  8. Financial Intermediation and the Funding of Biomedical Innovation
    A Review
    Author: Lo, Andrew W.; Thakor, Richard T.
    Published: October 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    We review the literature on financial intermediation in the process by which new medical therapeutics are financed, developed, and delivered. We discuss the contributing factors that lead to a key finding in the literature--underinvestment in... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    We review the literature on financial intermediation in the process by which new medical therapeutics are financed, developed, and delivered. We discuss the contributing factors that lead to a key finding in the literature--underinvestment in biomedical R&D--and focus on the role that banks and other intermediaries can play in financing biomedical R&D and potentially closing this funding gap. We conclude with a discussion of the role of financial intermediation in the delivery of healthcare to patients

     
    Export to reference management software   RIS file
      BibTeX file
  9. Strategic autonomy and long-term innovation competitiveness
    on the importance of intellectual property rights for the production of highvalue medicines in the EU
    Author: Bauer, Matthias
    Published: [2022]
    Publisher:  European Centre for International Political Economy, Brussels, Belgium

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    DS 567
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Other identifier:
    hdl: 10419/299149
    Series: ECIPE occasional paper ; 2022, 02
    Subjects: Immaterialgüterrechte; Pharmakologie; Arzneimittel; Innovation; Pharmaindustrie; Internationaler Wettbewerb; EU-Staaten
    Scope: 1 Online-Ressource (circa 90 Seiten), Illustrationen
  10. An Optimal Mechanism to Fund the Development of Vaccines Against Emerging Epidemics
    Author: Snyder, Christopher M.; Hoyt, Kendall; Gouglas, Dimitrios
    Published: November 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding cost-reimbursement contracts, requiring fixed-price contracts conditioned on delivery of a successful product. The high failure risk for individual vaccines calls for incentivizing multiple entrants, accomplished by the optimal mechanism, a (w+1)-price reverse Vickrey auction with reserve. Our analysis determines the optimal number of entrants and required funding level. Based on a distribution of supplier costs estimated from survey data, we simulate the optimal mechanism's performance in scenarios ranging from a small outbreak, causing harm in the millions of dollars, to the Covid-19 pandemic, causing harm in the trillions. We assess which mechanism features contribute most to its optimality

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: NBER working paper series ; no. w30619
    Subjects: Impfung; Epidemie; Pharmakologie; Technologiepolitik; Forschungsfinanzierung; Gesundheitswesen; Pharmaindustrie; Mechanismus-Design-Theorie; Market Design; Publicly Provided Goods: Mixed Markets; Government Policy; Regulation; Public Health; Chemicals; Rubber; Drugs; Biotechnology; Plastics; Innovation and Invention: Processes and Incentives
    Scope: 1 Online-Ressource, illustrations (black and white)
    Notes:

    Hardcopy version available to institutional subscribers
  11. The NBER Orange Book Dataset
    A User's Guide
    Author: Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa Larrimore; Sampat, Bhaven N.; Williams, Heidi
    Published: November 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry. We summarize the Orange Book's coverage and discuss the opportunities and challenges associated with using these data for research. Empirical validations against various administrative datasets suggest that Orange Book records are, largely, complete and accurate. We conclude with a specific use case--calculating legal exclusivity periods for drugs--to highlight the types of choices that researchers must make when using this resource

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: NBER working paper series ; no. w30628
    Subjects: Arzneimittel; Innovation; Pharmakologie; Pharmaindustrie; Patent; USA; General; Innovation; Research and Development; Technological Change; Intellectual Property Rights
    Scope: 1 Online-Ressource, illustrations (black and white)
    Notes:

    Hardcopy version available to institutional subscribers
  12. Regulatory Incentives for Innovation
    The FDA's Breakthrough Therapy Designation
    Author: Chandra, Amitabh; Kao, Jennifer L.; Miller, Kathleen L.; Stern, Ariel Dora
    Published: December 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to innovate around this tradeoff--i.e., whether it improved regulator productivity by allowing products to come to market more quickly without compromising quality. We find that the BTD program shortened clinical development times by 23 percent and did not impact the ex post safety profile of drugs with the designation. In exploring mechanisms, we find that the BTD program had the greatest impact on less experienced firms and was associated with reduced BTD clinical trial design complexity. The results suggest that targeted regulatory innovation can shorten R&D periods without compromising the quality of new products

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: NBER working paper series ; no. w30712
    Subjects: Arzneimittel; Innovation; Pharmakologie; Anreizregulierung; Gesundheitswesen; USA; General; Government Policy; Regulation; Public Health
    Scope: 1 Online-Ressource, illustrations (black and white)
    Notes:

    Hardcopy version available to institutional subscribers
  13. The Cost of Imbalance in Clinical Trials
    Author: Chassang, Sylvain; Feng, Rong
    Published: December 2022
    Publisher:  National Bureau of Economic Research, Cambridge, Mass

    Clinical trials following the "gold standard" of random assignment frequently use independent lotteries to allocate patients to treatment and control arms. However, independent assignment can generate treatment and control arms that are unbalanced... more

    Access:
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)

    Location:
    Sächsische Landesbibliothek - Staats- und Universitätsbibliothek Dresden
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Freiburg
    Inter-library loan:
    No inter-library loan

    Location:
    Helmut-Schmidt-Universität, Universität der Bundeswehr Hamburg, Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
    Inter-library loan:
    No inter-library loan

    Location:
    Technische Informationsbibliothek (TIB) / Leibniz-Informationszentrum Technik und Naturwissenschaften und Universitätsbibliothek
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan

     

    Clinical trials following the "gold standard" of random assignment frequently use independent lotteries to allocate patients to treatment and control arms. However, independent assignment can generate treatment and control arms that are unbalanced (i.e. treatment and control populations with significantly different demographics), which reduces power. Other assignment methods such as matched pair designs ensure balance across arms while maintaining randomization and permitting inference This paper seeks to measure the cost of imbalance with respect to gender in a sample of roughly 2000 clinical studies. We document significant imbalance: 25% of experiments have at least 26% more men in one treatment arm than in the other. In addition, clinical trials with greater imbalance have more dispersed treatment effects, indicating that imbalance reduces the informativeness of experiments. A simple structural model suggests that for a typical experiment, using a balanced random design could deliver informativeness gains equivalent to increasing the sample size by 18%

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: NBER working paper series ; no. w30745
    Subjects: Feldforschung; Medizin; Geschlechterdiskriminierung; Pharmakologie; Arzneimittel; Feldforschung; Medizin; Geschlechterdiskriminierung; General; Field Experiments; Government Policy; Regulation; Public Health; Other
    Scope: 1 Online-Ressource, illustrations (black and white)
    Notes:

    Hardcopy version available to institutional subscribers
  14. The economic case for UK investment in the Covid-19 pandemic response in 2022
    Author: Agarwal, Prachi; Lemma, Alberto; Velde, Dirk Willem te; White, Lucy
    Published: 22 June 2022
    Publisher:  ODI, London

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: ODI report
    Subjects: Coronavirus; Impfung; Pharmakologie; Finanzierung; Wirkungsanalyse; Großbritannien
    Scope: 1 Online-Ressource (circa 58 Seiten), Illustrationen